Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases
The FURTHER study aims to evaluate the effectiveness and cost-effectiveness of MR-HIFU (alone or in combination with EBRT) compared to EBRT alone, the standard-of-care, as a palliative treatment option to relieve CIBP. The FURTHER study consists of a multicenter, three-armed randomized controlled trial (FURTHER RCT) and a patient registry arm (FURTHER Registry), which will be performed in six hospitals in four European countries.
• Patient capable of giving informed consent
• Age ≥ 18 years
• Painful metastatic bone lesion (NRS \> 2)
• Patient-localised pain with a distinct pathological substrate on recent CT/MRI
• Target lesion location is sufficiently accessible for MR-HIFU to expect clinical response, as judged by the (intervention) radiologist
• Participant has a reasonable performance score (KPS ≥ 50% or Zubrod/ECOG/WHO \< 3)
• Life expectancy ≥ 3 months